RhumbLine Advisers
CARL

RhumbLine Advisers’s Carlsmed CARL Stock Holding History

RhumbLine Advisers’s Portfolio CARL Stock Details CARL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$46.9K Buy
5,181
+762
+17% +$9.21K ﹤0.01% 3600
2025
Q4 		$54.6K Sell
4,419
-1,484
-25% -$19.8K ﹤0.01% 3619
2025
Q3 		$79K Buy
+5,903
New +$80.7K ﹤0.01% 3580

Other funds holding CARL

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KC
KCM Capital Shawnee, Kansas $622M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RhumbLine Advisers's CARL Position: Q1 2026 in Review

RhumbLine Advisers increased its Carlsmed (CARL) stake by 17% in Q1 2026, buying an estimated $9.21K and bringing the position to 5,181 shares worth $46.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3600.

RhumbLine Advisers first reported a position in CARL in Q3 2025 and has held it in 3 quarters since. The position peaked at $79K in Q3 2025. 66 funds tracked by Wall St. Rank hold CARL as of Q1 2026.

  • RhumbLine Advisers held 5,181 shares of Carlsmed worth $46.9K as of Q1 2026.
  • RhumbLine Advisers bought 762 Carlsmed shares in Q1 2026, an estimated $9.21K.
  • Carlsmed made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #3600 holding.
  • RhumbLine Advisers first reported a position in Carlsmed in Q3 2025 and has held it in 3 quarters since.
  • RhumbLine Advisers's Carlsmed position peaked at $79K in Q3 2025.
  • 66 funds tracked by Wall St. Rank held Carlsmed as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.